Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

14.73 -0.10 (-0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Best and Worst Russell 1000 Stocks So Far in June
Right at the midpoint of June, Biogen has been the top-performing Russell 1,000 stock month to date. 
Via Talk Markets
10 Monster Stock Market Predictions For The Week Of June 14
The big question is what’s next for the S&P 500. Monday morning will likely decide what happens next. It would not be surprising to a reversion to the beginning of the wedge at 4070 over the next... 
Via Talk Markets
Topics Stocks
Exposures US Equities
What 18 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish... 
Via Benzinga
Bitcoin May Be Ready To Melt As It Nears Another Massive Breaking Point
It was another rather boring day, with the S&P 500 finishing basically flat down 8 bps. The Nasdaq 100 had the better day. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stocks Drop On May 5 As Inflation Rises And Growth Slows
Stocks finished mostly lower, with the S&P 500 up just 7 bps, while the Qs fell by almost 35 bps. The index had been higher nearly all day and fell sharply going into the final hour of trading. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021
Upgrades According to Argus Research, the prior rating for Zoom Video Communications Inc (NASDAQ:ZM) was changed from Hold to Buy. Zoom Video Communications earned $1.32... 
Via Benzinga
Cramer Gives His Opinion On Lemonade, Pinterest And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he still likes Lemonade Inc (NYSE: LMND). Investors will have to wait a long time for the value of the stock... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock rose 5.26% to $1.2 during Tuesday's after-market session. This security traded at a volume of 43.6K shares come close, making up... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows. Interesting Highlights: The largest company by market cap to set a new 52-week low was Ionis Pharmaceuticals (... 
Via Benzinga
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 13 companies achieved new lows for the year. Intriguing Points: The largest company by market cap to set a new 52-week low was Cia Paranaense De... 
Via Benzinga
Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over
Regulatory and drug-pricing worries have knocked biotech stocks off their pedestal. After hitting a high point in February, biotech stocks have fallen 20%. 
Via Investor's Business Daily
Exposures COVID-19
10 Biggest Price Target Changes For Wednesday
Keybanc raised Applied Materials, Inc. (NASDAQ: AMAT) price target from $144 to $151. Applied Materials shares rose 0.1% to $139.65 in pre-market trading. Needham boosted SMART... 
Via Benzinga
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021
Upgrades According to Janney Capital, the prior rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) was changed from Neutral to Buy. Texas Capital Bancshares earned $1.... 
Via Benzinga
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.